Skip to main content
PMC home page
Annals of Surgery logoLink to Annals of Surgery
. 1999 Jan;229(1):97–105. doi: 10.1097/00000658-199901000-00013

Surgical management of Merkel cell carcinoma.

P J Allen 1, Z F Zhang 1, D G Coit 1
PMCID: PMC1191614  PMID: 9923806

Abstract

OBJECTIVES: To characterize the natural history of Merkel cell carcinoma (MCC) and to analyze the influence of patient, tumor, and treatment-related variables on survival and recurrence. SUMMARY BACKGROUND DATA: Approximately 425 cases of MCC have been described in the literature. This study represents the largest experience reported. METHODS: A review was performed of patients who had been treated at Memorial Sloan-Kettering Cancer Center for MCC between 1969 and 1996. Follow-up data were available for 102 of the 109 (94%) patients identified. RESULTS: The overall 5-year disease-specific survival rate was 74%. The median follow-up was 35 months. For all patients, the only independent predictor of survival was the tumor stage at presentation. For patients with stage I disease, the tumor size at presentation was also an independent predictor of survival. Recurrence of disease occurred in 55 patients (55%), and the most common site of first recurrence was within the draining lymph nodes (n = 35). Elective lymph node dissection was the only parameter independently predictive of improved relapse-free survival. The overall disease-specific survival rate after recurrence was 62%. Predictors of improved disease-specific survival after recurrence included nodal as compared to local or distant recurrence, the ability to render the patient free of disease after recurrence, and a disease-free interval of >8 months. CONCLUSION: The prognosis for patients with MCC is favorable, and even after recurrence the majority of patients experience long-term survival. Incorporation of size into the staging system more accurately predicts survival in patients with stage I disease. Although elective lymph node dissection decreased the rate of recurrence, it was not associated with improved overall survival.

Full text

PDF
103

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azagury M., Chevallier B., Atlan D., Graic Y., Dayot J. P., Thomine E. VP-16, cisplatin, doxorubicin, and bleomycin in metastatic Merkel cell carcinoma. Report of a case with long-term remission. Am J Clin Oncol. 1993 Apr;16(2):102–104. doi: 10.1097/00000421-199304000-00003. [DOI] [PubMed] [Google Scholar]
  2. Boyle F., Pendlebury S., Bell D. Further insights into the natural history and management of primary cutaneous neuroendocrine (Merkel cell) carcinoma. Int J Radiat Oncol Biol Phys. 1995 Jan 15;31(2):315–323. doi: 10.1016/0360-3016(93)E0110-R. [DOI] [PubMed] [Google Scholar]
  3. Choe W., Housini I., Mello A. M. Lymphoscintigraphy in a case of Merkel cell tumor. Clin Nucl Med. 1995 Oct;20(10):922–924. doi: 10.1097/00003072-199510000-00015. [DOI] [PubMed] [Google Scholar]
  4. Crown J., Lipzstein R., Cohen S., Goldsmith M., Wisch N., Paciucci P. A., Silverman L., Weiner M., Jaffrey I., Norton L. Chemotherapy of metastatic Merkel cell cancer. Cancer Invest. 1991;9(2):129–132. doi: 10.3109/07357909109044222. [DOI] [PubMed] [Google Scholar]
  5. Feun L. G., Savaraj N., Legha S. S., Silva E. G., Benjamin R. S., Burgess M. A. Chemotherapy for metastatic Merkel cell carcinoma. Review of the M.D. Anderson Hospital's experience. Cancer. 1988 Aug 15;62(4):683–685. doi: 10.1002/1097-0142(19880815)62:4<683::aid-cncr2820620406>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  6. Gould V. E., Moll R., Moll I., Lee I., Franke W. W. Neuroendocrine (Merkel) cells of the skin: hyperplasias, dysplasias, and neoplasms. Lab Invest. 1985 Apr;52(4):334–353. [PubMed] [Google Scholar]
  7. Hitchcock C. L., Bland K. I., Laney R. G., 3rd, Franzini D., Harris B., Copeland E. M., 3rd Neuroendocrine (Merkel cell) carcinoma of the skin. Its natural history, diagnosis, and treatment. Ann Surg. 1988 Feb;207(2):201–207. doi: 10.1097/00000658-198802000-00015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Meeuwissen J. A., Bourne R. G., Kearsley J. H. The importance of postoperative radiation therapy in the treatment of Merkel cell carcinoma. Int J Radiat Oncol Biol Phys. 1995 Jan 15;31(2):325–331. doi: 10.1016/0360-3016(94)E0145-A. [DOI] [PubMed] [Google Scholar]
  9. Messina J. L., Reintgen D. S., Cruse C. W., Rappaport D. P., Berman C., Fenske N. A., Glass L. F. Selective lymphadenectomy in patients with Merkel cell (cutaneous neuroendocrine) carcinoma. Ann Surg Oncol. 1997 Jul-Aug;4(5):389–395. doi: 10.1007/BF02305551. [DOI] [PubMed] [Google Scholar]
  10. Pectasides D., Moutzourides G., Dimitriadis M., Varthalitis J., Athanassiou A. Chemotherapy for Merkel cell carcinoma with carboplatin and etoposide. Am J Clin Oncol. 1995 Oct;18(5):418–420. doi: 10.1097/00000421-199510000-00011. [DOI] [PubMed] [Google Scholar]
  11. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Pilotti S., Rilke F., Bartoli C., Grisotti A. Clinicopathologic correlations of cutaneous neuroendocrine Merkel cell carcinoma. J Clin Oncol. 1988 Dec;6(12):1863–1873. doi: 10.1200/JCO.1988.6.12.1863. [DOI] [PubMed] [Google Scholar]
  13. Pitale M., Sessions R. B., Husain S. An analysis of prognostic factors in cutaneous neuroendocrine carcinoma. Laryngoscope. 1992 Mar;102(3):244–249. doi: 10.1288/00005537-199203000-00003. [DOI] [PubMed] [Google Scholar]
  14. Raaf J. H., Urmacher C., Knapper W. K., Shiu M. H., Cheng E. W. Trabecular (Merkel cell) carcinoma of the skin. Treatment of primary, recurrent, and metastatic disease. Cancer. 1986 Jan 1;57(1):178–182. doi: 10.1002/1097-0142(19860101)57:1<178::aid-cncr2820570134>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  15. Ratner D., Nelson B. R., Brown M. D., Johnson T. M. Merkel cell carcinoma. J Am Acad Dermatol. 1993 Aug;29(2 Pt 1):143–156. doi: 10.1016/0190-9622(93)70159-q. [DOI] [PubMed] [Google Scholar]
  16. Shack R. B., Barton R. M., DeLozier J., Rees R. S., Lynch J. B. Is aggressive surgical management justified in the treatment of Merkel cell carcinoma? Plast Reconstr Surg. 1994 Dec;94(7):970–975. doi: 10.1097/00006534-199412000-00010. [DOI] [PubMed] [Google Scholar]
  17. Sharma D., Flora G., Grunberg S. M. Chemotherapy of metastatic Merkel cell carcinoma: case report and review of the literature. Am J Clin Oncol. 1991 Apr;14(2):166–169. doi: 10.1097/00000421-199104000-00014. [DOI] [PubMed] [Google Scholar]
  18. Shaw J. H., Rumball E. Merkel cell tumour: clinical behaviour and treatment. Br J Surg. 1991 Feb;78(2):138–142. doi: 10.1002/bjs.1800780205. [DOI] [PubMed] [Google Scholar]
  19. Smith D. E., Bielamowicz S., Kagan A. R., Anderson P. J., Peddada A. V. Cutaneous neuroendocrine (Merkel cell) carcinoma. A report of 35 cases. Am J Clin Oncol. 1995 Jun;18(3):199–203. doi: 10.1097/00000421-199506000-00004. [DOI] [PubMed] [Google Scholar]
  20. Tang C. K., Toker C. Trabecular carcinoma of the skin: an ultrastructural study. Cancer. 1978 Nov;42(5):2311–2321. doi: 10.1002/1097-0142(197811)42:5<2311::aid-cncr2820420531>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  21. Tennvall J., Biörklund A., Johansson L., Akerman M. Merkel cell carcinoma: management of primary, recurrent and metastatic disease. A clinicopathological study of 17 patients. Eur J Surg Oncol. 1989 Feb;15(1):1–9. [PubMed] [Google Scholar]
  22. Toker C. Trabecular carcinoma of the skin. Arch Dermatol. 1972 Jan;105(1):107–110. [PubMed] [Google Scholar]
  23. Wynne C. J., Kearsley J. H. Merkel cell tumor. A chemosensitive skin cancer. Cancer. 1988 Jul 1;62(1):28–31. doi: 10.1002/1097-0142(19880701)62:1<28::aid-cncr2820620107>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  24. Yiengpruksawan A., Coit D. G., Thaler H. T., Urmacher C., Knapper W. K. Merkel cell carcinoma. Prognosis and management. Arch Surg. 1991 Dec;126(12):1514–1519. doi: 10.1001/archsurg.1991.01410360088014. [DOI] [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES